# Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

> **NCT05561387** · PHASE3 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 510 (estimated)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Daratumumab and Hyaluronidase-fihj
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05561387
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-12
- **Primary completion:** 2031-05-30
- **Final completion:** 2031-05-30
- **Target enrollment:** 510 (ESTIMATED)
- **Last updated:** 2025-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05561387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05561387, "Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05561387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*